Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

CancerVax Ends Development of Melanoma Vaccine Canvaxin

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

CancerVax is dropping development of its cancer vaccine Canvaxin after a data safety monitoring board concludes a Phase III trial in stage III melanoma will not show a survival benefit.

You may also be interested in...



Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine

Company says it is the first to submit a therapeutic cancer vaccine application to FDA.

Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine

Company says it is the first to submit a therapeutic cancer vaccine application to FDA.

Antigenics Improves Oncophage Vaccine Manufacturing Output Ahead Of Registration Trial

Non-registration Phase III trial shows extension in survival for Oncophage-treated arm in category M1a stage IV melanoma.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS061204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By